Tell your doctor about any side effect that bothers you or that does not go away. 0000001126 00000 n The most common side effects in people with aHUS treated with SOLIRIS include: headache, diarrhea, high blood pressure (hypertension), common cold (upper respiratory infection), stomach-area (abdominal) pain, vomiting, pain or swelling of your nose or throat (nasopharyngitis), low red blood cell count (anemia), cough, swelling of legs or feet (peripheral edema), nausea, urinary tract infections, and fever. Tell your doctor or nurse right away if you get any of these symptoms during your SOLIRIS infusion: chest pain, trouble breathing or shortness of breath, swelling of your face, tongue, or throat, and feel faint or pass out. 97 0 obj <> endobj xref 97 33 0000000016 00000 n Meningococcal vaccines reduce but do not prevent all meningococcal infections. The accepted abstracts are listed below and are now available on the AAN website. Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a first-in-class amyloid fibril targeted therapy, have been accepted for presentation at the 62 nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually from December 5 to 8, 2020. gMG can occur at any age but most commonly begins before the age of 40 in women and after the age of 60 in men. In patients with these antibodies, NMOSD occurs when the complement system—a part of the body’s immune system—over-responds—leading the body to primarily attack the optic nerves and/or spinal cord in the CNS. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Type Industry Therapeutic Update. ... Industry Therapeutic Update from Alexion Pharmaceuticals, Inc. Make sure your child receives vaccinations against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) if treated with SOLIRIS. Certain people may be at risk of serious infections with gonorrhea. Alexion's 2019 Annual Meeting of Shareholders will be held on Tuesday, May 14, 2019, at the Seaport Hotel, 1 Seaport Lane, Boston MA 02210, at 5:30 p.m. local time. To learn more about the regulatory status of SOLIRIS in the countries that we serve, please visit www.alexion.com. Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a first-in-class amyloid fibril targeted therapy, have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually from December 5 to 8, 2020 0000002162 00000 n Your doctor will give you a Patient Safety Card about the risk of meningococcal infection. Kindly observe the following Rules of Conduct and Procedures. SOLIRIS can cause serious side effects including serious infusion-related reactions. Information about Alexion's directors and executive officers is available in Alexion's proxy statement for its 2020 annual meeting of stockholders, which … Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support 0000001168 00000 n 0000004114 00000 n About Neuromyelitis Optica Spectrum Disorder (NMOSD) x�}R�n�0��>���GH%�H#q�C%� b/)R1�!����&M"�X�����嶔�H��� Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that three abstracts have been accepted for presentation at the 73 rd annual meeting of the American Academy of Neurology (AAN), taking place virtually from April 17 through April 22, 2021. If you have an infusion-related reaction to SOLIRIS, your doctor may need to infuse SOLIRIS more slowly, or stop SOLIRIS. 0000002625 00000 n People living with NMOSD often experience unpredictable attacks, also referred to as relapses, which tend to be severe and recurrent and may result in permanent disability. %PDF-1.4 %���� x�c```b``������#� Ȁ �@1V�m*@�c�\S��# ��� ePoster presentation, Program Number P15.055, Session P15: MS Clinical Practice and Decision Making. 0000004608 00000 n The most common side effects in people with NMOSD treated with SOLIRIS include: common cold (upper respiratory infection), pain or swelling of your nose or throat (nasopharyngitis), diarrhea, back pain, dizziness, flu like symptoms (influenza) including fever, headache, tiredness, cough, sore throat, and body aches, joint pain (arthralgia), throat irritation (pharyngitis), and bruising (contusion). SOLIRIS® (eculizumab) is a first-in-class C5 complement inhibitor. What is the most important information I should know about SOLIRIS? 0000004354 00000 n – Data highlight long-term and real-world efficacy of SOLIRIS® (eculizumab) in patients living with rare neurologic complement-mediated disorders, including neuromyelitis optica spectrum disorder (NMOSD) and generalized myasthenia gravis (gMG) –. 0000011060 00000 n In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that three abstracts have been accepted for presentation at the 73rd annual meeting of the American Academy of Neurology (AAN), taking place virtually from April 17 through April 22, 2021. Welcome to the Annual Meeting of Shareholders (the “Annual Meeting”) of Alexion Pharmaceuticals, Inc. (the “Corporation”). You must receive meningococcal vaccines at least 2 weeks before your first dose of SOLIRIS if you are not vaccinated. Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology Seven Generations Energy Announces Conditional Redemption of All of Its 6.750% Senior Notes Due 2023, 6.875% Senior Notes Due 2023 and 5.375% Senior Notes Due 2025 SOLIRIS is only available through a program called the SOLIRIS REMS. The most common side effects in people with gMG treated with SOLIRIS include: muscle and joint (musculoskeletal) pain. 0000001694 00000 n FҴRh���@pl���D�|����V�o��4�Е��4%��)���b#�. Time 07:00 PM - 08:00 PM EDT. SOLIRIS is a prescription medicine used to treat: It is not known if SOLIRIS is safe and effective in children with PNH, gMG, or NMOSD. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. 0000005413 00000 n Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition. 4, 2021-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that three abstracts have been accepted for presentation at the 73 rd annual meeting of the American Academy of Neurology (AAN), taking place virtually from April 17 through April 22, 2021. adults with a disease called neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive. If you had a meningococcal vaccine in the past, you might need additional vaccination. Posters will be available throughout the duration of the Congress. 2015 Alexion Financial Support to Patient Advocacy Organization Osteogenesis Imperfecta Federation Europe (OIFE) Support for the organization’s annual meeting and seminar bringing together patients and clinicians. Your doctor will decide if you need additional vaccination. Call your doctor for medical advice about side effects. This press release and further information about Alexion can be found at: www.alexion.com. Executive Director, Corporate Communications, Investors Meeting Materials. Annual Meeting and Exposition, taking place virtually from December 5 to 8, 2020. MG typically begins with weakness in the muscles that control the movements of the eyes and eyelids and often progresses to the more severe and generalized form, known as generalized myasthenia gravis (gMG). You are encouraged to report negative side effects of prescription drugs to the FDA. If your doctor decided that urgent treatment with SOLIRIS is needed, you should receive meningococcal vaccination as soon as possible. x�]��j�0��~ �Cq��v��2�a�X�pl%3,�Q�C�~�:����?�[��];� ��c�ѓc\��a�ɓ:W�M{Wn;������$�;�j��".�78T�m��(�^L��A��9�}�N��9>��P�����K4�Є���Zh��Z����;5���pv?� 9�'��)���|~ �o' © 2021 Alexion Pharmaceuticals, Inc. full Prescribing Information and Medication Guide, https://www.businesswire.com/news/home/20210304006110/en/. Alexion will host its 2020 annual meeting of shareholders virtually due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of meeting participants. It is our desire to conduct a fair and informative Annual Meeting. The 2020 ACMG Digital Edition of the Annual Clinical Genetics Meeting presents both research and clinical topics that promote the science and the practice of clinical genetics and genomics. The most common side effects in people with PNH treated with SOLIRIS include: headache, pain or swelling of your nose or throat (nasopharyngitis), back pain, and nausea. 0000001748 00000 n Proxy Statement; Annual Report; Rules of Conduct . Do not receive SOLIRIS if you have a meningococcal infection or have not been vaccinated against meningitis infection unless your doctor decides that urgent treatment with SOLIRIS is needed. People with gMG can suffer from slurred speech, choking, difficulty swallowing, drooping of the eyelids, double or blurred vision, disabling fatigue, immobility requiring assistance, shortness of breath and episodes of respiratory failure that can be life-threatening. 0000017179 00000 n If you have PNH, your doctor will need to monitor you closely for at least 8 weeks after stopping SOLIRIS. Tell your doctor about all the vaccines you receive and medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements which could affect your treatment. Generalized Myasthenia Gravis (gMG) Head of Investor Relations, We use cookies to give you the best online experience. adults and children with a disease called atypical Hemolytic Uremic Syndrome (aHUS). If you have aHUS, your doctor will need to monitor you closely during and for at least 12 weeks after stopping treatment for signs of worsening aHUS symptoms or problems related to abnormal clotting (thrombotic microangiopathy). 0000004985 00000 n Additionally, long-term data on SOLIRIS for the treatment of neuromyelitis optica spectrum disorder (NMOSD) will be presented, including a disease model assessing the benefits of treatment and Phase 3 PREVENT clinical trial results evaluating SOLIRIS as a monotherapy. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that nine abstracts have been accepted for presentation at the 72nd annual meeting of the American Academy of Neurology (AAN) in Toronto, Ontario, Canada from April 25 through May 1, 2020. 1. adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. It is important to show this card to any doctor or nurse to help them diagnose and treat you quickly. In many countries around the world, SOLIRIS is approved to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), adults with generalized myasthenia gravis (gMG) who are acetylcholine receptor (AchR) antibody positive and/or adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that nine abstracts have been accepted for presentation at the 72nd annual meeting of the American Academy of Neurology (AAN) in Toronto, Ontario, Canada from April 25 through May 1, 2020. 0000003671 00000 n Symptoms or problems that can happen with abnormal clotting may include: stroke, confusion, seizure, chest pain (angina), difficulty breathing, kidney problems, swelling in arms or legs, and a drop in your platelet count. SOLIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections. ePoster presentation, Program Number P2.062, Session P2: Autoimmune Neurology: Inflammatory Neuropathies and Stiff Person Syndrome. BOSTON--(BUSINESS WIRE)--Nov. 6, 2019-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that five scientific data presentations from the company’s complement program will be showcased during the annual meeting of the American Society of Hematology (ASH) in Orlando, Fla., from Dec. 7 to 10, 2019. BOSTON--( )--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that nine abstracts from its complement research and development program have been accepted for presentation at the American Society of Hematology (ASH) Annual Meeting in San Diego, December 1 to 4, 2018. Before you receive SOLIRIS, tell your doctor about all of your medical conditions, including if you: have an infection or fever, are pregnant or plan to become pregnant, and are breastfeeding or plan to breastfeed. Stopping treatment with SOLIRIS may cause breakdown of your red blood cells due to PNH. Carry it with you at all times during treatment and for 3 months after your last SOLIRIS dose. Alexion will host its 2020 annual meeting of shareholders virtually due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of meeting participants. Long-Term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder. Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune disease of the central nervous system (CNS). 0000001367 00000 n 0000000978 00000 n Welcome to ALEXION PHARMACEUTICALS, INC.'s Annual Meeting of Shareholders. By using our website, you agree to our use of cookies in accordance with our, Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. * ALEXION ANNOUNCES UPCOMING DATA PRESENTATIONS AT 72ND ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY Source text for Eikon: Further company coverage: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that nine abstracts have been accepted for presentation at the 72nd annual meeting of the American Academy of Neurology (AAN) in Toronto, Ontario, Canada from April 25 through May 1, 2020. The business of the Annual Meeting will be taken up as set forth in the Agenda. SOLIRIS may also increase the risk of other types of serious infections. View source version on businesswire.com: https://www.businesswire.com/news/home/20210304006110/en/, Media The disease primarily affects women, with an average age of onset of 39 years. Myasthenia gravis (MG) is a rare, progressive, autoimmune neuromuscular disease. Germany 10,000 EUR Associazione A.M.E.N.A. Alexion will host its 2020 annual meeting of shareholders virtually due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of meeting participants. 4, 2021-- 0000003422 00000 n This website is intended only for residents of the United States. 0000001802 00000 n When activated in an uncontrolled manner, the terminal complement cascade over-responds, leading the body to attack its own healthy cells. 0000003385 00000 n 0000004282 00000 n patients with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH) . About SOLIRIS® 0000003153 00000 n Profile. Annual Meeting Annual Meeting AAN Annual Meeting: Grow professionally and connect with colleagues at the world’s largest gathering of neurologists and neuroscience professionals. 0000003698 00000 n Complications, exacerbations and myasthenic crises can require hospital and intensive care unit admissions with prolonged stays. 0000005976 00000 n Long-term safety and efficacy results from the Phase 3 PREVENT study and open-label extension of SOLIRIS (eculizumab) in […] Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that six abstracts have been accepted for presentation at the 62 nd Annual Meeting and Exposition of the American Society of Hematology (ASH), taking place virtually from December 5 to 8, 2020. 0000002301 00000 n As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). SOLIRIS is not indicated for the treatment of patients with Shiga-toxin E. coli-related hemolytic uremic syndrome (STEC-HUS). Symptoms or problems that can happen due to red blood cell breakdown include: drop in the number of your red blood cell count, drop in your platelet count, confusion, kidney problems, blood clots, difficulty breathing, and chest pain. NMOSD is more common and more severe in non-Caucasian populations worldwide. Certain fungal infections (Aspergillus) may occur if you take SOLIRIS and have a weak immune system or a low white blood cell count. ET Comments Call your doctor or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms, and eyes sensitive to light. What are the possible side effects of SOLIRIS? Ask your doctor if you are not sure if you need to be revaccinated. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In patients with anti-acetylcholine receptor (AchR) antibody-positive MG, the body’s own immune system over-responds, leading the body to attack its own healthy cells and produce antibodies to fight against AchR, a receptor located on muscle cells at the neuromuscular junction. The most common symptoms of NMOSD are optic neuritis, which can cause visual problems including blindness, and transverse myelitis, which can cause mobility problems including paralysis. SOLIRIS is not for use in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). If you have not been vaccinated and SOLIRIS therapy must be initiated immediately, you should also receive two weeks of antibiotics with your vaccinations. BOSTON--(BUSINESS WIRE)--Mar. Date Sunday 04/18/21. If the meeting does not begin automatically, please click the play button on the audio section of the media player. Megan Goulart, 857-338-8634 Approximately three-quarters of NMOSD patients have anti-AQP4 antibody-positive NMOSD. endstream endobj 100 0 obj <>/MediaBox [0 0 612 792]/Parent 3 0 R/Resources <>/Font <>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]>>/StructParents 0/Tabs /S/Type /Page>> endobj 101 0 obj <> endobj 102 0 obj <> endobj 103 0 obj <> endobj 104 0 obj <> endobj 105 0 obj <> endobj 106 0 obj <> endobj 107 0 obj <> endobj 108 0 obj [110 0 R] endobj 109 0 obj <> stream 0000002598 00000 n New real-world data will be presented evaluating SOLIRIS® (eculizumab) for the treatment of generalized myasthenia gravis (gMG) in the United States, suggesting substantial reductions in myasthenic crises, exacerbations and related hospitalizations, consistent with results from the Phase 3 REGAIN clinical trial and the open-label extension. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that three abstracts have been accepted for presentation at the 73rd annual meeting of …
Polizei Wilhelmshaven Twitter, Bitburger Braugruppe Aktie, Temps Additionnel Paris Sportif, Hbf Dental Providers Brisbane, Mike Singer Tour 2021, Bip-deflator über 1, Bombe Trier Twitter, Religionsunterricht Abmelden Baden-württemberg, Unfall Herzlake Heute, Mvumbi Handball Größe,